Check out our deep dive in MSI-H gastric cancer, now out in @CD_AACR . Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer

📢 Ph1/2 FOG-001 — a first-in-class β-catenin/TCF inhibitor — shows early promise in MSS CRC & WPAM+ solid tumors ✅ ORR 43% in non-CRC WPAM+ solid tumors ✅ No grade 4/5 TRAEs ➡️ Combo & monotherapy cohorts underway #Targets25

Nice way to end the week. Pre-print from our team. @arnavmehta3 @JeeyunM @AnMinae, others. Support from @SU2C @AACR. @MGHCancerCenter Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer

A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal #cancers and highlight the rapid expansion of claudin18.2-targeting drug development in solid tumors. News & Views from @KlempnerSam and @sundar__raghav

Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by @KlempnerSam and myself in @NatureMedicine we discuss two promising Claudin18.2 targeting Antibody-Drug Conjugates.

Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... https://t.co/lNe0glc9aD Led by very talented @josephjzhao and Kennedy Ng. @sundar__raghav

Givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in mGEC 🔎Phase I/II 👉ORR 71% 🧐 Interesting activity #ESMOAmbassadors #ESMOGI25 @myESMO

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b https://t.co/pFuyP5LnL5.

Enjoying interacting with other speakers and discussants during today’s plenary. Exciting new data was presented.

Attending the #AACR25 session on Innovative Paradigms in Immunotherapy Combos in Gastric Cancer? Read speaker @KlempnerSam's recent @CD_AACR paper: Early Immune Remodeling Steers Clinical Response to Frontline Chemoimmunotherapy in Advanced Gastric Cancer https://t.co/zfDtS5Dirq

Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial https://t.co/9Ib0j2ycXq @JeeyunM @AnMinae @arnavmehta3 @CCR_AACR

Proof of principle in KRAS G12C CRC, analogous to EGFR rechallenge in RAS WT Colon cancer. @MGHCancerCenter @JCOPO_ASCO Anti-KRAS G12C + Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer.

Cool paper from @ShadiEsfahani and team in @ScienceTM @MGHCancerCenter Development of a fibrin-targeted theranostic for gastric cancer | Science Translational Medicine

SCI members @HowardYChang, @mischellab, and others found that blocking #CHK1 activity leads to death of #ecDNA containing tumor cells and tumor regression in mice with a gastric tumor driven by DNA circles.  https://t.co/5LPSWh4um6

Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy | Journal of Clinical Oncology

Adding to the ever growing approaches in GEA. @JCO_ASCO @ASCO. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish |

Great to have another option for patients. @KoheiShitara @mdmanishshah @ILSONDavid @FlorianLordick @sara_lonardi1 and many others. FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma https://t.co/l5CqX7YQd8 via @onclive

Pleased to share final survival results of two phase 3 of zolbetuximab @NEJM  which reinforce zolbetuxumab plus chemo as effective treatment option, though still need better treatment. More agents will be coming for CLDN18.2+ GC @myESMO @OncoAlert #ESMO24

Building one of the largest datasets of gastric cancer peritoneal metastases in the world, we unravel new biology of organotropism, the important role of the tumor microenvironment and novel biomarkers. Just published in Gastroenterology! @josephjzhao https://t.co/mtEoYrtVoO

Congratulations to Harsh Singh and @DanaFarber team for getting this data out. CAPOX + Trastuzumab + Bevacizumab in frontline HER2+ gastroesophageal. @NatureComms @JamesClearyMD @DrRonanKelly and others https://t.co/kS4kbJ94iv -- full paper https://t.co/aYgof3SyCB

I'd like to call attn. to an outstanding professional development opportunity, the @ASCO Leadership Development Program! I served as a Board liaison mentor & can't overemphasize the impact LDP can have on the career trajectory of participants. Apply here: